Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.
Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.15). On average, analysts expect Acurx Pharmaceuticals to post ($2.00) EPS for the current fiscal year and ($1.60) EPS for the next fiscal year.
Acurx Pharmaceuticals Stock Down 1.9%
ACXP opened at $1.04 on Wednesday. The firm has a market capitalization of $5.78 million, a P/E ratio of -0.39 and a beta of -2.08. The firm’s 50 day moving average is $1.24 and its 200-day moving average is $1.92. Acurx Pharmaceuticals has a 52-week low of $0.95 and a 52-week high of $7.54.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on ACXP shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating on shares of Acurx Pharmaceuticals in a research report on Tuesday, September 29th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.
Get Our Latest Analysis on Acurx Pharmaceuticals
Acurx Pharmaceuticals Company Profile
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. The company’s research is centered on therapies designed to address pathogens that are resistant to existing treatments. Acurx’s lead product candidate is ibezapolstat, also known as ACX-375, an investigational oral antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C. difficile infection.
Read More
- Five stocks we like better than Acurx Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
